Cost-Effectiveness of 12 First-Line Treatments for Patients With Advanced EGFR Mutated NSCLC in the United Kingdom and China

Overview of attention for article published in Frontiers in oncology, June 2022

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 27 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 1 X users, with an upper bound of 6,534 followers.

#1: Cost-Effectiveness of 12 First-Line Treatments for Patients With Advanced EGFR Mutated NSCLC in the United Kingdom and China 👩‍⚕️👨‍⚕️ Haijing Guan et al Read now 👉 https://t.co/CZCcjxULHL #LungCancer #LCsm #NSCLC

10 Jun 2022

Reply Repost Favourite

New research: Cost-Effectiveness of 12 First-Line Treatments for Patients With Advanced EGFR Mutated NSCLC in the United Kingdom and China: Background Lung cancer is imposing significant pressure on the national health insurance system… https://t.co/2KXNK

07 Jun 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.